drugset / Trial / NCT02293967

Mass Balance Study of MT-1303

NCT02293967

Phase 1 Completed 8 enrolled Tanabe Pharma Corporation
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the absorption, metabolism and excretion of MT-1303 in healthy subjects.

Timeline

Start
2014-09
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject amiselimod Small molecule 0.4 mg Oral